Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
PaperCitations, authors & open-access status
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 418 citations, 2023 year and hybrid oa status.
418
Citations
2023
Year
hybrid
OA Status